Literature DB >> 28209676

What is hidradenitis suppurativa?

Erika Yue Lee1, Raed Alhusayen2, Perla Lansang3, Neil Shear4, Jensen Yeung5.   

Abstract

OBJECTIVE: To provide family physicians with an understanding of the epidemiology, clinical features, diagnosis, and management of hidradenitis suppurativa (HS). SOURCES OF INFORMATION: A PubMed literature search was performed using the MeSH term hidradenitis suppurativa. MAIN MESSAGE: Hidradenitis suppurativa is a chronic, recurrent, and debilitating skin condition. It is an inflammatory disorder of the follicular epithelium, but secondary bacterial infection can often occur. The diagnosis is made clinically based on typical lesions (nodules, abscesses, sinus tracts), locations (skin folds), and nature of relapses and chronicity. Multiple comorbidities are associated with HS, including obesity, metabolic syndrome, inflammatory bowel disease, and spondyloarthropathy. Although the lack of curative therapy and the recurrent nature makes HS treatment challenging, there are effective symptomatic management options.
CONCLUSION: Family physicians should be suspicious of HS in patients presenting with recurrent skin abscesses at the skin folds. Family physicians play an important role in early diagnosis, initiation of treatment, and referral to a dermatologist before HS progresses to debilitating end-stage disease. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28209676      PMCID: PMC5395382     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  40 in total

1.  Clindamycin and rifampicin combination therapy for hidradenitis suppurativa.

Authors:  C O Mendonça; C E M Griffiths
Journal:  Br J Dermatol       Date:  2006-05       Impact factor: 9.302

2.  Surgical treatment of sinuses by deroofing in hidradenitis suppurativa.

Authors:  Simone van Hattem; Julia R Spoo; Barbara Horváth; Marcel F Jonkman; Fredrik W J Leeman
Journal:  Dermatol Surg       Date:  2011-12-30       Impact factor: 3.398

3.  Hidradenitis suppurativa markedly decreases quality of life and professional activity.

Authors:  Łukasz Matusiak; Andrzej Bieniek; Jacek C Szepietowski
Journal:  J Am Acad Dermatol       Date:  2010-04       Impact factor: 11.527

4.  Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study.

Authors:  Florence Canoui-Poitrine; Aurélie Le Thuaut; Jean E Revuz; Cédric Viallette; Germaine Gabison; Florence Poli; Florence Pouget; Pierre Wolkenstein; Sylvie Bastuji-Garin
Journal:  J Invest Dermatol       Date:  2012-12-13       Impact factor: 8.551

5.  A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.

Authors:  I Miller; C D Lynggaard; S Lophaven; C Zachariae; D N Dufour; G B E Jemec
Journal:  Br J Dermatol       Date:  2011-06-30       Impact factor: 9.302

Review 6.  Hidradenitis suppurativa.

Authors:  F William Danby; Lynette J Margesson
Journal:  Dermatol Clin       Date:  2010-10       Impact factor: 3.478

7.  Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.

Authors:  G Gener; F Canoui-Poitrine; J E Revuz; O Faye; F Poli; G Gabison; F Pouget; C Viallette; P Wolkenstein; S Bastuji-Garin
Journal:  Dermatology       Date:  2009-07-08       Impact factor: 5.366

Review 8.  γ-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis.

Authors:  Andrew E Pink; Michael A Simpson; Nemesha Desai; Richard C Trembath; Jonathan N W Barker
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

9.  Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.

Authors:  Alexa B Kimball; Francisco Kerdel; David Adams; Ulrich Mrowietz; Joel M Gelfand; Robert Gniadecki; Errol P Prens; Joel Schlessinger; Christos C Zouboulis; Hessel H van der Zee; Marie Rosenfeld; Parvez Mulani; Yihua Gu; Susan Paulson; Martin Okun; Gregor B E Jemec
Journal:  Ann Intern Med       Date:  2012-12-18       Impact factor: 25.391

10.  Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa.

Authors:  G B Jemec; P Wendelboe
Journal:  J Am Acad Dermatol       Date:  1998-12       Impact factor: 11.527

View more
  12 in total

1.  Family physicians' role in hidradenitis suppurativa management.

Authors:  Valerio De Vita
Journal:  Can Fam Physician       Date:  2017-05       Impact factor: 3.275

2.  Hidradenitis Suppurativa in a Patient Affected by Mayer-Rokitansky-Küster-Hauser Syndrome: Insight into the Role of Hormones in HS.

Authors:  Angelo Ruggiero; Gabriella Fabbrocini; Matteo Megna; Giuseppe Monfrecola; Claudio Marasca
Journal:  Skin Appendage Disord       Date:  2020-10-19

3.  Hidradenitis suppurativa associated with systemic lupus erythematosus: A case report.

Authors:  Chen Ben David; Nicola L Bragazzi; Abdulla Watad; Kassem Sharif; Aaron Whitby; Howard Amital; Mohammad Adawi
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

4.  Knowledge about and determinants for diagnosing hidradenitis suppurativa by ministry of health primary healthcare physicians in Jeddah city 2019: An analytical cross-sectional study.

Authors:  Ebtisam M F Alhawsawi; Ghufran A Hariri; Randa J Alzuhayri; Yahya Makhdoom
Journal:  J Family Med Prim Care       Date:  2020-03-26

5.  Phenotypic and genotypic virulence features of staphylococcal strains isolated from difficult-to-treat skin and soft tissue infections.

Authors:  Mădălina Preda; Mara Mădălina Mihai; Laura Ioana Popa; Lia-Mara Dițu; Alina Maria Holban; Loredana Sabina Cornelia Manolescu; Gabriela-Loredana Popa; Andrei-Alexandru Muntean; Irina Gheorghe; Carmen Mariana Chifiriuc; Mircea-Ioan Popa
Journal:  PLoS One       Date:  2021-02-02       Impact factor: 3.240

Review 6.  Aquaporins Are One of the Critical Factors in the Disruption of the Skin Barrier in Inflammatory Skin Diseases.

Authors:  Paola Maura Tricarico; Donatella Mentino; Aurora De Marco; Cecilia Del Vecchio; Sabino Garra; Gerardo Cazzato; Caterina Foti; Sergio Crovella; Giuseppe Calamita
Journal:  Int J Mol Sci       Date:  2022-04-05       Impact factor: 5.923

Review 7.  Efficacy and Toxicity of Classical Immunosuppressants, Retinoids and Biologics in Hidradenitis Suppurativa.

Authors:  Kinnor Das; Steven Daveluy; George Kroumpouzos; Komal Agarwal; Indrashis Podder; Katherine Farnbach; Alex G Ortega-Loayza; Jacek C Szepietowski; Stephan Grabbe; Mohamad Goldust
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

8.  Prevalence of low vitamin D levels in patients with Hidradenitis suppurativa in Jordan: A comparative cross-sectional study.

Authors:  Khaled Seetan; Batool Eldos; Muthanna Saraireh; Rami Omari; Yousef Rubbai; Anas Jayyusi; Maha Abu Jubran
Journal:  PLoS One       Date:  2022-03-18       Impact factor: 3.240

9.  Comparison of Split Thickness Skin Grafts and Flaps in Bilateral Chronic Axillary Hidradenitis Suppurativa.

Authors:  Abolfazl Afsharfard; Mohammad Bashir Khodaparast; Sina Zarrintan; Negin Yavari
Journal:  World J Plast Surg       Date:  2020-01

10.  Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.

Authors:  Verena Gerlinde Frings; Oliver Schöffski; Matthias Goebeler; Dagmar Presser
Journal:  PLoS One       Date:  2021-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.